The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 211
Maximum Observed Plasma Concentration (Cmax) of ABBV-1451
Timeframe: Up to Approximately Day 211
Time to Cmax (Tmax) of ABBV-1451
Timeframe: Up to Approximately Day 211
Terminal Phase Elimination Rate Constant (β) of ABBV-1451
Timeframe: Up to Approximately Day 211
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1451
Timeframe: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-1451
Timeframe: Up to Approximately Day 211
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-1451
Timeframe: Up to Approximately Day 211